{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:14:40Z","timestamp":1793420080151,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0395"],"award-info":[{"award-number":["W81XWH-22-1-0395"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CG Oncology, Moffitt Cancer Center, Campbell Family Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41591-024-03324-9","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T11:01:51Z","timestamp":1731150111000},"page":"176-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-7200","authenticated-orcid":false,"given":"Roger","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Y.","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-9372","authenticated-orcid":false,"given":"Xiaoqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8857-0299","authenticated-orcid":false,"given":"Gustavo","family":"Borjas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-3487","authenticated-orcid":false,"given":"Jasreman","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8702-0554","authenticated-orcid":false,"given":"Carlos M.","family":"Moran-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngchul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3800-2645","authenticated-orcid":false,"given":"John J.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade J.","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Poch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Zemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1192-5116","authenticated-orcid":false,"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio M.","family":"Pow-Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-4383","authenticated-orcid":false,"given":"Alexander R. A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5775-408X","authenticated-orcid":false,"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Daniel","family":"Grass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P. N.","family":"Dinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-6566","authenticated-orcid":false,"given":"Paulo C.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-0516","authenticated-orcid":false,"given":"James J.","family":"Mul\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6431-4074","authenticated-orcid":false,"given":"Jose R.","family":"Conejo-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"key":"3324_CR1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666\u2013675 (2001).","journal-title":"J. Clin. Oncol."},{"key":"3324_CR2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859\u2013866 (2003).","journal-title":"N. Engl. J. Med."},{"key":"3324_CR3","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"International Collaboration of Trialists et al.","year":"2011","unstructured":"International Collaboration of Trialists et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171\u20132177 (2011).","journal-title":"J. Clin. Oncol."},{"key":"3324_CR4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","volume":"20","author":"TW Flaig","year":"2022","unstructured":"Flaig, T. W. et al. NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 2.2022. J. Natl Compr. Canc. Netw. 20, 866\u2013878 (2022).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"3324_CR5","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky, M. D. et al. Treatment of patients with metastatic urothelial cancer \u2018unfit\u2019 for cisplatin-based chemotherapy. J. Clin. Oncol. 29, 2432\u20132438 (2011).","journal-title":"J. Clin. Oncol."},{"key":"3324_CR6","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","volume":"26","author":"J Gao","year":"2020","unstructured":"Gao, J. et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat. Med. 26, 1845\u20131851 (2020).","journal-title":"Nat. Med."},{"key":"3324_CR7","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353\u20133360 (2018).","journal-title":"J. Clin. Oncol."},{"key":"3324_CR8","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706\u20131714 (2019).","journal-title":"Nat. Med."},{"key":"3324_CR9","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. 26, 1839\u20131844 (2020).","journal-title":"Nat. Med."},{"key":"3324_CR10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","volume":"12","author":"N Ramesh","year":"2006","unstructured":"Ramesh, N. et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2013armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res.12, 305\u2013313 (2006).","journal-title":"Clin. Cancer Res."},{"key":"3324_CR11","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","volume":"188","author":"JM Burke","year":"2012","unstructured":"Burke, J. M. et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J. Urol. 188, 2391\u20132397 (2012).","journal-title":"J. Urol."},{"key":"3324_CR12","doi-asserted-by":"publisher","unstructured":"Tyson M. D. et al. P2-02:\u2003Pivotal results from BOND-003: a phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. J. Urol. https:\/\/doi.org\/10.1097\/01.JU.0001015816.87470.c9.02 (2024).","DOI":"10.1097\/01.JU.0001015816.87470.c9.02"},{"key":"3324_CR13","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1200\/JCO.2024.42.16_suppl.4601","volume":"42","author":"R Li","year":"2024","unstructured":"Li, R. et al. Final results of CORE-001: a phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ. J. Clin. Oncol. 42, 4601 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3324_CR14","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","volume":"30","author":"R Li","year":"2024","unstructured":"Li, R. et al. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat. Med. 30, 2216\u20132223 (2024).","journal-title":"Nat. Med."},{"key":"3324_CR15","volume":"2","author":"P Dai","year":"2017","unstructured":"Dai, P. et al. Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci. Immunol. 2, eaal1713 (2017).","journal-title":"Sci. Immunol."},{"key":"3324_CR16","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","volume":"34","author":"N Packiriswamy","year":"2020","unstructured":"Packiriswamy, N. et al. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Leukemia 34, 3310\u20133322 (2020).","journal-title":"Leukemia"},{"key":"3324_CR17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34791-8","volume":"13","author":"J Svensson-Arvelund","year":"2022","unstructured":"Svensson-Arvelund, J. et al. Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. Nat. Commun. 13, 7149 (2022).","journal-title":"Nat. Commun."},{"key":"3324_CR18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","volume":"55","author":"A Shabsigh","year":"2009","unstructured":"Shabsigh, A. et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur. Urol. 55, 164\u2013174 (2009).","journal-title":"Eur. Urol."},{"key":"3324_CR19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2022.12.001","volume":"56","author":"A Chow","year":"2023","unstructured":"Chow, A. et al. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity 56, 93\u2013106 (2023).","journal-title":"Immunity"},{"key":"3324_CR20","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan, B. C. et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat. Med. 27, 1410\u20131418 (2021).","journal-title":"Nat. Med."},{"key":"3324_CR21","volume":"65","author":"JR Conejo-Garcia","year":"2023","unstructured":"Conejo-Garcia, J. R., Biswas, S., Chaurio, R. & Rodriguez, P. C. Neglected no more: B cell-mediated anti-tumor immunity. Semin. Immunol. 65, 101707 (2023).","journal-title":"Semin. Immunol."},{"key":"3324_CR22","doi-asserted-by":"crossref","unstructured":"Crichton, E. S., Zeng, S., La Muraglia, G. M. 2nd & Badell, I. R. CXCL13 is an indicator of germinal center activity and alloantibody formation following transplantation. Transplant Direct. 7, e785 (2021).","DOI":"10.1097\/TXD.0000000000001247"},{"key":"3324_CR23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527\u2013541 (2022).","journal-title":"Immunity"},{"key":"3324_CR24","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.cell.2022.02.012","volume":"185","author":"RD Mazor","year":"2022","unstructured":"Mazor, R. D. et al. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell 185, 1208\u20131222 (2022).","journal-title":"Cell"},{"key":"3324_CR25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"C Pfister","year":"2021","unstructured":"Pfister, C. et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG\/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur. Urol. 79, 214\u2013221 (2021.","journal-title":"Eur. Urol."},{"key":"3324_CR26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.euo.2023.11.022","volume":"7","author":"P Grivas","year":"2023","unstructured":"Grivas, P. et al. PrECOG PrE0807: a phase 1b feasibility trial of neoadjuvant nivolumab without and with lirilumab in patients with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based neoadjuvant chemotherapy. Eur. Urol. Oncol. 7, 914\u2013922 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"3324_CR27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2022.40.6_suppl.498","volume":"40","author":"BJ Guercio","year":"2022","unstructured":"Guercio, B. J. et al. Neoadjuvant nivolumab (N) +\/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). J. Clin. Oncol. 40, 498 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3324_CR28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/JCO.2021.39.6_suppl.442","volume":"39","author":"VS Koshkin","year":"2021","unstructured":"Koshkin, V. S. et al. Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy. J. Clin. Oncol. 39, 442 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3324_CR29","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2022.40.16_suppl.4517","volume":"40","author":"N Martinez Chanza","year":"2022","unstructured":"Martinez Chanza, N. et al. Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial. J. Clin. Oncol. 40, 4517 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3324_CR30","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","volume":"29","author":"J van Dorp","year":"2023","unstructured":"van Dorp, J. et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat. Med. 29, 588\u2013592 (2023).","journal-title":"Nat. Med."},{"key":"3324_CR31","first-page":"507","volume":"38","author":"XX Wei","year":"2020","unstructured":"Wei, X. X. et al. Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2. J. Clin. Oncol. 38, 507 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3324_CR32","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1200\/JCO.2024.42.16_suppl.4516","volume":"42","author":"J Blanc","year":"2024","unstructured":"Blanc, J. et al. Avelumab (A) as neoadjuvant therapy in patients (pts) with muscle-invasive urothelial carcinoma (MIUC): survival data of AURA trial, Oncodistinct 004. J. Clin. Oncol. 42, 4516 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3324_CR33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados, B. et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur. Urol. 82, 212\u2013222 (2022).","journal-title":"Eur. Urol."},{"key":"3324_CR34","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat. Med. 29, 2825\u20132834 (2023).","journal-title":"Nat. Med."},{"key":"3324_CR35","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41585-021-00483-z","volume":"18","author":"R Li","year":"2021","unstructured":"Li, R., Zhang, J., Gilbert, S. M., Conejo-Garcia, J. & Mul\u00e9, J. J. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nat. Rev. Urol. 18, 543\u2013555 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"3324_CR36","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh, D. Y. et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181, 1612\u20131625 (2020).","journal-title":"Cell"},{"key":"3324_CR37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.immuni.2021.12.007","volume":"55","author":"RA Chaurio","year":"2022","unstructured":"Chaurio, R. A. et al. TGF-\u03b2-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity 55, 115\u2013128 (2022).","journal-title":"Immunity"},{"key":"3324_CR38","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nri.2016.94","volume":"16","author":"H Qi","year":"2016","unstructured":"Qi, H. T follicular helper cells in space-time. Nat. Rev. Immunol. 16, 612\u2013625 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"3324_CR39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"3324_CR40","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1200\/JCO.2008.17.6149","volume":"26","author":"D Coppola","year":"2008","unstructured":"Coppola, D. & Mul\u00e9, J. J. Ectopic lymph nodes within human solid tumors. J. Clin. Oncol. 26, 4369\u20134370 (2008).","journal-title":"J. Clin. Oncol."},{"key":"3324_CR41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajpath.2011.03.007","volume":"179","author":"D Coppola","year":"2011","unstructured":"Coppola, D. et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 179, 37\u201345 (2011).","journal-title":"Am. J. Pathol."},{"key":"3324_CR42","doi-asserted-by":"crossref","DOI":"10.1038\/srep00765","volume":"2","author":"JL Messina","year":"2012","unstructured":"Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012).","journal-title":"Sci. Rep."},{"key":"3324_CR43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"3324_CR44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"3324_CR45","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"3324_CR46","volume":"12","author":"N van Dijk","year":"2021","unstructured":"van Dijk, N. et al. The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer. Front. Immunol. 12, 793964 (2021).","journal-title":"Front. Immunol."},{"key":"3324_CR47","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-023-05771-9","volume":"616","author":"KW Ng","year":"2023","unstructured":"Ng, K. W. et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature 616, 563\u2013573 (2023).","journal-title":"Nature"},{"key":"3324_CR48","doi-asserted-by":"publisher","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. https:\/\/doi.org\/10.14806\/ej.17.1.200 (2011).","DOI":"10.14806\/ej.17.1.200"},{"key":"3324_CR49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"3324_CR50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).","journal-title":"BMC Bioinformatics"},{"key":"3324_CR51","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2006","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118\u2013127 (2006).","journal-title":"Biostatistics"},{"key":"3324_CR52","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3324_CR53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene Ontology: tool for the unification of biology. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"3324_CR54","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"3324_CR55","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","volume":"75","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur. Urol. 75, 961\u2013964 (2019).","journal-title":"Eur. Urol."},{"key":"3324_CR56","doi-asserted-by":"crossref","first-page":"e0224693","DOI":"10.1371\/journal.pone.0224693","volume":"14","author":"SA Danziger","year":"2019","unstructured":"Danziger, S. A. et al. ADAPTS: automated deconvolution augmentation of profiles for tissue specific cells. PLoS ONE 14, e0224693 (2019).","journal-title":"PLoS ONE"},{"key":"3324_CR57","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","volume":"6","author":"K Ellrott","year":"2018","unstructured":"Ellrott, K. et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 6, 271\u2013281 (2018).","journal-title":"Cell Syst."},{"key":"3324_CR58","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"3324_CR59","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"3324_CR60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"3324_CR61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/bioinformatics\/btr665","volume":"28","author":"DE Larson","year":"2012","unstructured":"Larson, D. E. et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28, 311\u2013317 (2012).","journal-title":"Bioinformatics"},{"key":"3324_CR62","volume":"17","author":"Y Fan","year":"2016","unstructured":"Fan, Y. et al. MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. Genome Biol. 17, 178 (2016).","journal-title":"Genome Biol."},{"key":"3324_CR63","unstructured":"Garrison, E. P. & Marth, G. Haplotype-based variant detection from short-read sequencing. Preprint at https:\/\/arxiv.org\/abs\/1207.3907 (2012)."},{"key":"3324_CR64","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","volume":"25","author":"K Ye","year":"2009","unstructured":"Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865\u20132871 (2009).","journal-title":"Bioinformatics"},{"key":"3324_CR65","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811\u20131817 (2012).","journal-title":"Bioinformatics"},{"key":"3324_CR66","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2019).","journal-title":"Nucleic Acids Res."},{"key":"3324_CR67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285\u2013291 (2016).","journal-title":"Nature"},{"key":"3324_CR68","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","volume":"43","author":"SA Forbes","year":"2015","unstructured":"Forbes, S. A. et al. COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805\u2013D811 (2015).","journal-title":"Nucleic Acids Res."},{"key":"3324_CR69","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","volume":"29","author":"ST Sherry","year":"2001","unstructured":"Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308\u2013311 (2001).","journal-title":"Nucleic Acids Res."},{"key":"3324_CR70","volume":"2016","author":"BL Aken","year":"2016","unstructured":"Aken, B. L. et al. The Ensembl gene annotation system. Database 2016, baw093 (2016).","journal-title":"Database"},{"key":"3324_CR71","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"3324_CR72","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"3324_CR73","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","volume":"171","author":"I Martincorena","year":"2017","unstructured":"Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029\u20131041 (2017).","journal-title":"Cell"},{"key":"3324_CR74","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2018","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947 (2018).","journal-title":"Nucleic Acids Res."},{"key":"3324_CR75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/bioinformatics\/btz474","volume":"36","author":"R Orenbuch","year":"2019","unstructured":"Orenbuch, R. et al. arcasHLA: high-resolution HLA typing from RNAseq. Bioinformatics 36, 33\u201340 (2019).","journal-title":"Bioinformatics"},{"key":"3324_CR76","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/humu.23230","volume":"38","author":"S Kawaguchi","year":"2017","unstructured":"Kawaguchi, S., Higasa, K., Shimizu, M., Yamada, R. & Matsuda, F. HLA-HD: an accurate HLA typing algorithm for next-generation sequencing data. Hum. Mutat. 38, 788\u2013797 (2017).","journal-title":"Hum. Mutat."},{"key":"3324_CR77","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1101\/gr.277585.122","volume":"33","author":"L Song","year":"2023","unstructured":"Song, L., Bai, G., Liu, X. S., Li, B. & Li, H. Efficient and accurate KIR and HLA genotyping with massively parallel sequencing data. Genome Res. 33, 923\u2013931 (2023).","journal-title":"Genome Res."},{"key":"3324_CR78","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: improved peptide\u2013MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"3324_CR79","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/acs.jproteome.9b00874","volume":"19","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B. et al. Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data. J. Proteome Res. 19, 2304\u20132315 (2020).","journal-title":"J. Proteome Res."},{"key":"3324_CR80","volume":"11","author":"MS Hall","year":"2023","unstructured":"Hall, M. S. et al. Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. J. Immunother. Cancer 11, e007288 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"3324_CR81","doi-asserted-by":"crossref","unstructured":"Gouin, K. H. 3rd et al. An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer. Nat. Commun. 12, 4906 (2021).","DOI":"10.1038\/s41467-021-25103-7"},{"key":"3324_CR82","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s43018-022-00356-3","volume":"3","author":"T Chu","year":"2022","unstructured":"Chu, T., Wang, Z., Pe\u2019er, D. & Danko, C. G. Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology. Nat. Cancer 3, 505\u2013517 (2022).","journal-title":"Nat. Cancer"},{"key":"3324_CR83","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1541-0420.2005.00311.x","volume":"61","author":"A Ivanova","year":"2005","unstructured":"Ivanova, A., Qaqish, B. F. & Schell, M. J. Continuous toxicity monitoring in phase II trials in oncology. Biometrics 61, 540\u2013545 (2005).","journal-title":"Biometrics"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03324-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03324-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03324-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T18:05:06Z","timestamp":1737482706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03324-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3324"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03324-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3864301\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"14 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.L. reports research support from Predicine, Veracyte, CG Oncology, Valar Labs, Merck and Janssen; clinical trial protocol committee participation with CG Oncology, Merck and Janssen; and is scientific advisor\/consultant for Bristol Myers Quibb, Merck, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence, CG Oncology, Janssen, Thericon, Iconovir, ImmunityBio and Pfizer. W.J.S. reports consultant work for Pacific Edge and Urogen Pharma. P.E.S. reports being the Vice Chair of the NCCN guidelines committee for bladder and penile cancer. J.Z. reports consultant work for Sanofi, AstraZeneca, Dendreon, Seagen, Bayer and Pfizer. G.D.G. reports consultant work for MyCareGorithm and stock options in Lantheus. J.M.B. reports consultant work for CG Oncology and Kalivir Immunotherapeutics and being a shareholder of CG Oncology and Kalivir Immunotherapeutics. C.P.N.D. reports consultant work for AstraZeneca and CG Oncology and intellectual property ownership related to the use of genetic alterations as a predictive biomarker for response to nadofaragene firadenovec. R.K.J. reports consultant work for AVEO, Bristol Myers Squibb, Sanofi, EMD Serono, Gilead Sciences, IDEOlogy Pfizer and Seattle Genetics\/Astellas; speaker\u2019s bureau for Gilead Sciences, Seagen and Seattle Genetics\/Astellas; research funding from Bristol Myers Squibb, Gilead Sciences and the National Cancer Institute; and honoraria from FLASCO, Curio Science, DAVA Oncology, NCCN\/Pfizer and OncLive\/MJH Life Sciences. J.J.M. reports membership on the CG Oncology Board of Directors; being the Associate Center Director at Moffitt Cancer Center; ownership interest in Aleta Biotherapeutics, CG Oncology, Turnstone Biologics, Ankyra Therapeutics and AffyImmune Therapeutics; and consultant work for ONCoPEP, CG Oncology, Turnstone Biologics, Vault Pharma, Ankyra Therapeutics, AffyImmune Therapeutics, UbiVac, Vycellix and Aleta Biotherapeutics. J.R.C.-G. reports consultant work for Anixa Biosciences and Alloy Therapeutics; stock options in Compass Therapeutics, Anixa Biosciences and Alloy Therapeutics; patent licensed by Anixa Biosciences; intellectual property filed with Compass Therapeutics; and being the co-founder of Cellepus Therapeutics, a CAR T cell company. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}